86 related articles for article (PubMed ID: 21965720)
1. In vitro evaluation of targeted antisense 177Lu radiotherapy.
Balkin ER; Jia F; Miller WH; Lewis MR
Anticancer Res; 2011 Oct; 31(10):3143-9. PubMed ID: 21965720
[TBL] [Abstract][Full Text] [Related]
2. Targeted antisense radiotherapy and dose fractionation using a (177)Lu-labeled anti-bcl-2 peptide nucleic acid-peptide conjugate.
Liu D; Balkin ER; Jia F; Ruthengael VC; Smith CJ; Lewis MR
Nucl Med Biol; 2015 Sep; 42(9):704-10. PubMed ID: 26081917
[TBL] [Abstract][Full Text] [Related]
3. Comparative biodistributions and dosimetry of [¹⁷⁷Lu]DOTA-anti-bcl-2-PNA-Tyr³-octreotate and [¹⁷⁷Lu]DOTA-Tyr³-octreotate in a mouse model of B-cell lymphoma/leukemia.
Balkin ER; Liu D; Jia F; Ruthengael VC; Shaffer SM; Miller WH; Lewis MR
Nucl Med Biol; 2014 Jan; 41(1):36-42. PubMed ID: 24267052
[TBL] [Abstract][Full Text] [Related]
4. Copper-64-labeled anti-bcl-2 PNA-peptide conjugates selectively localize to bcl-2-positive tumors in mouse models of B-cell lymphoma.
Jia F; Balaji BS; Gallazzi F; Lewis MR
Nucl Med Biol; 2015 Nov; 42(11):809-15. PubMed ID: 26239085
[TBL] [Abstract][Full Text] [Related]
5. Molecular imaging of bcl-2 expression in small lymphocytic lymphoma using 111In-labeled PNA-peptide conjugates.
Jia F; Figueroa SD; Gallazzi F; Balaji BS; Hannink M; Lever SZ; Hoffman TJ; Lewis MR
J Nucl Med; 2008 Mar; 49(3):430-8. PubMed ID: 18287262
[TBL] [Abstract][Full Text] [Related]
6. Synthesis of radiometal-labeled and fluorescent cell-permeating peptide-PNA conjugates for targeting the bcl-2 proto-oncogene.
Gallazzi F; Wang Y; Jia F; Shenoy N; Landon LA; Hannink M; Lever SZ; Lewis MR
Bioconjug Chem; 2003; 14(6):1083-95. PubMed ID: 14624621
[TBL] [Abstract][Full Text] [Related]
7. Tyr3-octreotide and Tyr3-octreotate radiolabeled with 177Lu or 90Y: peptide receptor radionuclide therapy results in vitro.
Capello A; Krenning EP; Breeman WA; Bernard BF; Konijnenberg MW; de Jong M
Cancer Biother Radiopharm; 2003 Oct; 18(5):761-8. PubMed ID: 14629824
[TBL] [Abstract][Full Text] [Related]
8. A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu.
Konijnenberg MW; Bijster M; Krenning EP; De Jong M
J Nucl Med; 2004 Jul; 45(7):1260-9. PubMed ID: 15235075
[TBL] [Abstract][Full Text] [Related]
9. Comparison of [177Lu-DOTA0,Tyr3]-octreotate and [177Lu-DOTA0,Tyr3]-octreotide for receptor-mediated radiation therapy of the xenografted human midgut carcinoid tumor GOT1.
Swärd C; Bernhardt P; Johanson V; Schmitt A; Ahlman H; Stridsberg M; Forssell-Aronsson E; Nilsson O; Kölby L
Cancer Biother Radiopharm; 2008 Feb; 23(1):114-20. PubMed ID: 18298335
[TBL] [Abstract][Full Text] [Related]
10. The addition of DTPA to [177Lu-DOTA0,Tyr3]octreotate prior to administration reduces rat skeleton uptake of radioactivity.
Breeman WA; van der Wansem K; Bernard BF; van Gameren A; Erion JL; Visser TJ; Krenning EP; de Jong M
Eur J Nucl Med Mol Imaging; 2003 Feb; 30(2):312-5. PubMed ID: 12552352
[TBL] [Abstract][Full Text] [Related]
11. Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course.
Bergsma H; Konijnenberg MW; Kam BL; Teunissen JJ; Kooij PP; de Herder WW; Franssen GJ; van Eijck CH; Krenning EP; Kwekkeboom DJ
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):453-63. PubMed ID: 26419852
[TBL] [Abstract][Full Text] [Related]
12. DOTA conjugate with an albumin-binding entity enables the first folic acid-targeted 177Lu-radionuclide tumor therapy in mice.
Müller C; Struthers H; Winiger C; Zhernosekov K; Schibli R
J Nucl Med; 2013 Jan; 54(1):124-31. PubMed ID: 23236020
[TBL] [Abstract][Full Text] [Related]
13. A comparison of high- versus low-linear energy transfer somatostatin receptor targeted radionuclide therapy in vitro.
Nayak T; Norenberg J; Anderson T; Atcher R
Cancer Biother Radiopharm; 2005 Feb; 20(1):52-7. PubMed ID: 15778581
[TBL] [Abstract][Full Text] [Related]
14. Radiometal-labeled peptide-PNA conjugates for targeting bcl-2 expression: preparation, characterization, and in vitro mRNA binding.
Lewis MR; Jia F; Gallazzi F; Wang Y; Zhang J; Shenoy N; Lever SZ; Hannink M
Bioconjug Chem; 2002; 13(6):1176-80. PubMed ID: 12440850
[TBL] [Abstract][Full Text] [Related]
15. Bulk Scale Formulation of Therapeutic Doses of Clinical Grade Ready-to-Use
Mathur A; Prashant V; Sakhare N; Chakraborty S; Vimalnath KV; Mohan RK; Arjun C; Karkhanis B; Seshan R; Basu S; Korde A; Banerjee S; Dash A; Sachdev SS
Cancer Biother Radiopharm; 2017 Sep; 32(7):266-273. PubMed ID: 28910148
[TBL] [Abstract][Full Text] [Related]
16. 177Lu-labeled RGD-BBN heterodimeric peptide for targeting prostate carcinoma.
Jiang L; Miao Z; Liu H; Ren G; Bao A; Cutler CS; Shi H; Cheng Z
Nucl Med Commun; 2013 Sep; 34(9):909-14. PubMed ID: 23708872
[TBL] [Abstract][Full Text] [Related]
17. Biodistribution and dosimetry of 177Lu-labeled [DOTA0,Tyr3]octreotate in male nude mice with human small cell lung cancer.
Schmitt A; Bernhardt P; Nilsson O; Ahlman H; Kölby L; Schmitt J; Forssel-Aronsson E
Cancer Biother Radiopharm; 2003 Aug; 18(4):593-9. PubMed ID: 14503955
[TBL] [Abstract][Full Text] [Related]
18. Tumoral fibrosis effect on the radiation absorbed dose of (177)Lu-Tyr(3)-octreotate and (177)Lu-Tyr(3)-octreotate conjugated to gold nanoparticles.
Azorín-Vega EP; Zambrano-Ramírez OD; Rojas-Calderón EL; Ocampo-García BE; Ferro-Flores G
Appl Radiat Isot; 2015 Jun; 100():96-100. PubMed ID: 25305748
[TBL] [Abstract][Full Text] [Related]
19. New peptide receptor radionuclide therapy of invasive cancer cells: in vivo studies using 177Lu-DOTA-AE105 targeting uPAR in human colorectal cancer xenografts.
Persson M; Rasmussen P; Madsen J; Ploug M; Kjaer A
Nucl Med Biol; 2012 Oct; 39(7):962-9. PubMed ID: 22739362
[TBL] [Abstract][Full Text] [Related]
20. Radiation dosimetry is a necessary ingredient for a perfectly mixed molecular radiotherapy cocktail.
Savolainen S; Konijnenberg M; Bardiès M; Lassmann M; Strigari L; Chiesa C; Chiti A; Reijonin V; Flux G
Eur J Nucl Med Mol Imaging; 2012 Mar; 39(3):548-9. PubMed ID: 22241725
[No Abstract] [Full Text] [Related]
[Next] [New Search]
